STOCK TITAN

Beta Bionics CFO Stephen Feider sells 744 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) Chief Financial Officer Stephen Feider exercised 744 options on November 9, 2026, at $5.10 per share, acquiring 744 common shares, then sold 744 shares at a weighted average of $17.001344 per share. The sale was made under a Rule 10b5-1 plan adopted July 31, 2026. His reported option position after the exercise was 38,569.

Insider Feider Stephen
Role Chief Financial Officer
Sold 744 shs ($13K)
Approx. gross sale proceeds $13K
Approx. exercise cost $4K
Approx. pre-tax spread $9K
Share of Position Sold 0.46%
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F3 744 $0.00 $0.00
Exercise Common Stock 744 $5.10 $4K
Sale Common Stock F1, F2 744 $17.0013 $13K
Holdings After Transaction: Employee Stock Option (right to buy) — 38,569 options (Direct); Common Stock — 159,378 shares (Direct)
Holdings Before and After: Employee Stock Option (right to buy), 39,313 to 38,569 options (Direct); Common Stock, 159,378 to 159,378 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
  1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2026.
  2. F2. The weighted average sale price for the transaction reported was $17.001344 and the range of prices were between $17.00 and $17.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. F3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Options exercised 744 options November 9, 2026
Exercise price $5.10 per share Options exercised November 9, 2026
Common shares acquired 744 shares Upon exercise on November 9, 2026
Shares sold 744 shares November 9, 2026
Weighted average sale price $17.001344 per share Sale of 744 shares; reported range was $17.00 to $17.01 per share
Reported option position after exercise 38,569 Following the November 9, 2026 exercise
Vesting installments 48 equal monthly installments Measured from September 14, 2023
Rule 10b5-1 Plan regulatory
"shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2026"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $17.001344"
vest financial
"shares subject to this option shall vest in 48 equal monthly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBNX shares did the chief financial officer sell, and at what price?

Stephen Feider sold 744 shares on November 9, 2026, at a weighted average price of $17.001344 per share. The reported sale prices ranged from $17.00 to $17.01, and the sale was under a Rule 10b5-1 plan adopted July 31, 2026.

How many BBNX options did Stephen Feider exercise?

Stephen Feider exercised 744 options at $5.10 per share on November 9, 2026, acquiring 744 common shares. His reported option position after the exercise was 38,569.

How do Stephen Feider's BBNX options vest?

The options vest in 48 equal monthly installments, measured from September 14, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feider Stephen

(Last)(First)(Middle)
C/O BETA BIONICS, INC.
11 HUGHES

(Street)
IRVINE CALIFORNIA 92618

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/09/2026M744A$5.1160,122D
Common Stock11/09/2026S(1)744D$17.0013(2)159,378D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$5.111/09/2026M744 (3)09/13/2033Common Stock744$0.0038,569D
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2026.
2. The weighted average sale price for the transaction reported was $17.001344 and the range of prices were between $17.00 and $17.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Remarks:
/s/ Thomas Sohn, Attorney-in-Fact11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading